)

Zai Lab (ZLAB) investor relations material
Zai Lab Morgan Stanley 23rd Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Company overview and recent performance
Founded in 2014, with IPOs on NASDAQ and Hong Kong Stock Exchange; employs staff in 17 countries, mainly China.
Eight commercial products launched, with two more expected to gain approval by early next year.
Global pipeline includes DLL3 ADC in pivotal trials and internally discovered IL-13/31 entering phase one in the U.S. this year.
Focus areas are oncology, immunology, and neurology, with key products like KarXT and a fast-growing Genix partner product.
Reported $400 million in sales last year and holds $800 million in cash.
Strategic approach to in-licensing and innovation
Remains interested in China rights for synergistic assets, especially in oncology, immunology, and neurology.
Selective about global rights, focusing on areas of strong internal expertise and combining internal discovery with external innovation.
Leverages deep market knowledge and clinical site expertise in China for in-licensing opportunities.
Balances internal discovery (1–2 INDs/year) with early-phase business development globally, focusing on best-in-class innovation.
Sees increasing innovation opportunities in China, especially in oncology and immunology.
Pipeline highlights and clinical development
DLL3 ADC shows 79% ORR in targeted dose with mild safety profile; aims for accelerated U.S. approval in late 2027.
October update expected on second-line small cell lung cancer durability data; first-line combination data anticipated early next year.
Neuroendocrine tumor trials ongoing, with potential breakthrough if response rates reach 20%.
POVI (IgAN nephropathy) chosen for large market potential in China, aiming for best-in-class status despite competition.
VYVGART positioned as frontline GMG therapy in China; NRDL listing for sub-Q version targeted for 2026.
Next Zai Lab earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage